Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment

International Journal of Pharmaceutics

Volumn 468, Issue 1-2, 2014, Pages 178-186

  Bose, A ^a,b   Elyagoby, A ^a,b   Wong, T W ^a,b,c  

^a Faculty of Pharmacy   (Malaysia)

^b Non Destructive Biomedical and Pharmaceutical Research Centre   (Malaysia)

^c UNIVERSITI TEKNOLOGI MARA   (Malaysia)

Author keywords

5 Fluorouracil; Colon cancer; Colon specific drug delivery; In vivo pellet coating

Indexed keywords

ETHYL CELLULOSE; FLUOROURACIL; PECTIN; ANTINEOPLASTIC ANTIMETABOLITE; CELLULOSE; DIMETHYLHYDRAZINE; ENTERIC COATED TABLET; POWDER;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BASEMENT MEMBRANE; CANCER SIZE; COLON ADENOCARCINOMA; COLON ADENOMA; COLON CANCER; COLON SPECIFIC DRUG DELIVERY SYSTEM; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG PELLET; DRUG RELEASE; DRUG SOLUBILITY; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR PROBE; NONHUMAN; PARTICLE SIZE; PELLET EXTRUSION; PREFORMULATION; PRIORITY JOURNAL; RAT; SPHERONIZATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ABERRANT CRYPT FOCI; ADENOCARCINOMA; ADENOMA; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMICALLY INDUCED; CHEMISTRY; COLONIC NEOPLASMS; DRUG EFFECTS; ENTERIC COATED TABLET; MEDICINAL CHEMISTRY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHARMACEUTICS; POWDER; PROCEDURES; SOLUBILITY; SPRAGUE DAWLEY RAT; TUMOR VOLUME;

ABERRANT CRYPT FOCI; ADENOCARCINOMA; ADENOMA; ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; COLONIC NEOPLASMS; DIMETHYLHYDRAZINES; DRUG DELIVERY SYSTEMS; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; PECTINS; POWDERS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TABLETS, ENTERIC-COATED; TECHNOLOGY, PHARMACEUTICAL; TUMOR BURDEN;

EID: 84899678433     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.04.006     Document Type: Article

References (27)

1. S. Ai, T. Jia, W. Ai, J. Duan, Y. Liu, J. Chen, X. Liu, F. Yang, Y. Tian, and Z. Huang Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells British Journal of Pharmacology 168 2013 1719 1735
2. M. Arellano, M. Malet-Martino, R. Martino, and P. Gires The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate British Journal of Cancer 7 1998 79 86
3. P. Boyle, and M.E. Leon Recent developments in the epidemiology of colorectal cancer H. Bleiberg, N. Kemeny, P. Rougier, H. Wilke, Colorectal Cancer - A Clinical Guide to Therapy 2002 Taylor and Francis UK 11 29
4. A. Elyagoby, N. Layas, and T.W. Wong Colon-specific delivery of 5-fluorouracil from zinc pectinate pellets through in situ intra-capsular ethylcellulose-pectin plug formation Journal of Pharmaceutical Sciences 102 2013 604 616
5. A.K. Garmaise, A.E. Rogers, C.A. Saravis, N. Zamcheck, and P.M. Newberne Immunologic aspects of 1,2-dimethylhydrazine-induced colon tumors in rats Journal of the National Cancer Institute 54 1975 1231 1235
6. T. Goto, N. Tomizawa, E. Kobayashi, and A. Fujimura A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yoshida Sarcoma rat model Journal de Pharmacologie Science 95 2004 163 173
7. N. Gupta, P.M. Price, and E.O. Aboagye PET for in vivo pharmacokinetic and pharmacodynamic measurements European Journal of Cancer 38 2002 2094 2107
8. I.T. Johnson New approaches to the role of diet in the prevention of cancers of the alimentary tract Mutation Research 551 2004 9 28
9. D. Lieberman Colorectal cancer screening and surveillance G.G. Ginsberg, M.L. Kochman, I. Norton, C.J. Gostout, Clinical Gastrointestinal Endoscopy 2005 Elservier UK 537 547
10. D.J. MacEwan Emerging therapeutic aspects in oncology British Journal of Pharmacology 169 2013 1647 1651
11. R. Matuo, F.G. Sousa, A.E. Escargueil, I. Grivicich, D. Garcia-Santos, J.A.B. Chies, J. Saffi, A.K. Larsen, and J.A.P. Henriques 5-fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line Journal of Applied Toxicology 29 2009 308 316
12. R.S. Midgley, A. Merrie, D.J. Kerr, and N. Mortensen Colorectal cancer: a multidisciplinary approach W.M. Weinstein, C.J. Hawkey, J. Bosch, Clinical Gastroenterology and Hepatology 2005 Elsevier Spain 421 430
13. T. Nie, C.C. Wong, N. Alston, P. Aro, P.P. Constantinides, and B. Rigas Phospho-ibuprofen (MDC-917) incorporated in nanocarriers: anti-cancer activity in vitro and in vivo British Journal of Pharmacology 166 2012 991 1001
14. Paharia A.; Yadav A.K.; Rai G.; Jain S.K.; Pancholi S.S.; Agrawal G.P.; Eudragit-coated pectin microspheres of 5-fluorouracil for colon targeting. AAPS PharmSciTech 8, 2007, Article 12.
15. J.E. Paulsen, E. Namork, and J. Alexander Scanning electron microscopy of colonic lesions in 1,2-dimethylhydrazine-treated rats Anticancer Research 25 2005 3883 3888
16. R. Porschen, A. Bermann, T. Loffler, G. Haack, K. Rettig, Y. Anger, and G. Strohmeyer Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: Results of the trial adjCCA- 01 Journal of Clinical Oncology 19 2001 1787 1794
17. D.W. Rosenberg, C. Giardina, and T. Tanaka Mouse models for the study of colon carcinogenesis Carcinogenesis 30 2009 183 196
18. S.E. Salmon, and A.C. Sartorelli Cancer chemotherapy B.G. Katzung, Basic and Clinical Pharmacology 1992 Prentice-Hall International Inc. USA 766 800
19. R. Soetikno, S. Friedland, T. Matsuda, and T. Gotoda Colonoscopic polypectomy and endoscopic mucosal resection G.G. Ginsberg, M.L. Kochman, I. Norton, C.J. Gostout, Clinical Gastrointestinal Endoscopy 2005 Elservier UK 549 568
20. L. Strate, E. Pieramici, and D. Ahnen Biology and genetics of colorectal cancer W.M. Weinstein, C.J. Hawkey, J. Bosch, Clinical Gastroenterology and Hepatology 2005 Elsevier Spain 397 406
21. N. Tanaka, K. Kataoka, M. Muro, K. Kojima, S. Horiki, M. Ono, L.F. Moreira, Y. Naomoto, and K. Orita In vivo augmentation of the intratumoral concentration of 5-fluorouracil by cepharanthine - a biscoclaurine alkaloid In Vivo 8 1994 309 311
22. A.J.M. Watson An overview of apoptosis and the prevention of colorectal cancer Critical Reviews in Oncology/Hematology 57 2006 107 121
23. H. Wei, D. Qing, C. De-Ying, X. Bai, and F. Li-Fang Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats International Journal of Pharmaceutics 348 2008 35 45
24. T.W. Wong, G. Colombo, and F. Sonvico Pectin matrix as oral drug delivery vehicle for colon cancer treatment AAPS PharmSciTech 12 2011 201 214
25. World Health Organization, 2009. Health topics. http://www.who.int/ topics/cancer/en (accessed on 25.02.2009).
26. World Health Organization, 2013. Global cancer rates could increase by 50% to 15 million by 2020. http://www.who.int/mediacentre/news/releases/2003/ pr27/en/ (accessed 04.03.2013).
27. E.F. Yen Colon neoplasms A. Shiels, T.L. Lin, The Washington Manual™ Gastroenterology Subspecialty Consult 2004 Lippincott Williams & Wilkins USA 93 100